Grey Matters Health Signs LOI with Catalyst MedTech for Alzheimer’s Clinical Trial
Grey Matters Health Inc. has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech to provide 200 brain PET scans for an upcoming Alzheimer’s Disease clinical trial at its planned NovaScan location in Tampa, Florida. This agreement is expected to lead to a definitive services agreement within 60 days. The scans, which are less invasive than spinal taps, will support clinical trials for new AD drugs requiring confirmed diagnoses. The collaboration aims to address the growing demand in neurological clinical research and patient care.
VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) — Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer’s Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company’s NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida. The parties will work towards signing a definitive services agreement in the next 60 days.